ChemotherapyFDA-approvedFirst-line
FOLFOX
Generic name: oxaliplatin
How it works
Forms platinum-DNA adducts, causing DNA damage and cancer cell death.
Cancer types
Colorectal Cancer— All patients
Efficacy
Clinical trials demonstrate that FOLFOX can improve overall survival in patients with metastatic colorectal cancer, with a median survival of approximately 19 months.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing New Treatment for Colorectal Cancer Spreading to the Peritoneum | Colorectal Cancer | phase-1 | — | Source → |
| MYC Protein Linked to Resistance to Cancer Treatment | Colorectal Cancer | lab-study | — | Source → |
| Cancer Cells' Chemical Signals May Indicate Resistance to Treatment | Colorectal Cancer | lab-study | — | Source → |
| Metastatic Pancreatic Cancer Trial Investigates New Treatment Approach | Pancreatic Cancer | phase-2 | — | Source → |
| Huaier Sensitizes Colorectal Cancer to Oxaliplatin | Colorectal Cancer | lab-study | — | Source → |
| Artesunate May Help Overcome Resistance to Cancer Treatment in Colorectal Cancer | Colorectal Cancer | lab-study | — | Source → |
| Ethanol May Contribute to Colorectal Cancer Resistance to Treatment | Colorectal Cancer | lab-study | — | Source → |
| Studying Organ Preservation in Early Rectal Cancer Patients | Colorectal Cancer | phase-2 | — | Source → |
| Testing Chemo-Immunotherapy for Pancreatic Cancer | Pancreatic Cancer | phase-2 | — | Source → |
| Testing BOLD-100 in Combination with FOLFOX for Advanced Solid Tumors | Colorectal Cancer | phase-1 | — | Source → |
| Rectal Cancer Trial Examines New Treatment Combination | Colorectal Cancer | phase-2 | — | Source → |
| Testing a New Combination Therapy for Colorectal Cancer | Colorectal Cancer | phase-2 | — | Source → |
| Evaluating a Combination Treatment for Metastatic Colorectal Cancer in Elderly Patients | Colorectal Cancer | phase-2 | — | Source → |
| Testing Ivonescimab and Bevacizumab in Metastatic Colorectal Cancer | Colorectal Cancer | phase-3 | — | Source → |
| Preventing Nerve Damage in Cancer Patients | Colorectal Cancer | preclinical | — | Source → |
| New Treatment Combination Shows Promise for Colon Cancer Patients | Colorectal Cancer | phase-3 | The 3-year disease-free survival was 86.3% in the atezolizumab-mFOLFOX6 group, as compared with 76.2% in the mFOLFOX6 group. | Source → |
| Nicotine Affects Colon Cancer Treatment Efficacy | Colorectal Cancer | lab-study | — | Source → |
| Blueberry Anthocyanins Enhance Chemotherapy Effectiveness in Colon Cancer Cells | Colorectal Cancer | lab-study | The combination of blueberry anthocyanins and oxaliplatin significantly inhibited the proliferation and colony formation of HCT116 and LOVO cells (P<0.01) and markedly suppressed tumor growth in the nude mouse xenograft model (P<0.05). | Source → |
| New Diagnostic Tool for Colorectal Cancer Identified | Colorectal Cancer | lab-study | The diagnostic signature demonstrated robust performance in distinguishing resistant cases (AUC = 0.868). | Source → |
| Oxaliplatin-resistant colorectal cancer cells linked to specific proteins | Colorectal Cancer | lab-study | Silencing CHGA and UCHL1 genes effectively suppressed the mobility and invasiveness of OXA-resistant HCT-116/OxR cells while promoting G1 phase cell cycle arrest and reducing ROS production and intracellular calcium concentrations. | Source → |
| Comparing Second-Line Treatments for Pancreatic Cancer | Pancreatic Cancer | observational | 5-FU + Nal-IRI showed a median overall survival of 7.2 months, compared to 5.8 months for FOLFOX/XELOX. | Source → |
| Adding Panitumumab to Chemotherapy for Colon Cancer | Colorectal Cancer | phase-2 | There was a trend towards reduced recurrences with FOLFOX plus panitumumab compared with FOLFOX (12% versus 21%, hazard ratio = 0.51, P = 0.09) | Source → |
| LAMA3 Gene May Help Colon Cancer Respond Better to Oxaliplatin | Colorectal Cancer | lab-study | — | Source → |
| FOLFOX Chemotherapy Linked to Severe Potassium Deficiency | Colorectal Cancer | observational | — | Source → |
| Comparing Chemotherapy Options for Colorectal Cancer | Colorectal Cancer | phase-3 | Ox resulted in a significantly improved peritoneal recurrence-free survival in CC0/1 patients (MMC=9.0 versus Ox=12.6months, P = .01). | Source → |
| Long non-coding RNA linked to oxaliplatin resistance in colorectal cancer | Colorectal Cancer | lab-study | — | Source → |
| Oxaliplatin Side Effect Study in Colorectal Cancer Patients | Colorectal Cancer | phase-3 | — | Source → |
| New Treatment Shows Promise for Colorectal Cancer Patients | Colorectal Cancer | phase-1 | Compared with standard therapy, PIPAC-Oxaliplatin was associated with higher median good days at 6 months (181 vs 131 days; p = 0.042) and 1 year (323 vs 131 days; p = 0.032), and longer overall survival (median, 11.3 vs 5.1 months; p = 0.036). | Source → |
| Oxaliplatin Chemotherapy Less Effective in Colorectal Cancer with High WTAP Levels | Colorectal Cancer | lab-study | — | Source → |
| GL-V9 Enhances Effectiveness of Colorectal Cancer Treatment | Colorectal Cancer | lab-study | — | Source → |
| Rare Side Effect of Cancer Drug: Transient Ischemic Attack | Colorectal Cancer | observational | — | Source → |
| Combination Therapy Shows Promise Against Pancreatic Cancer | Pancreatic Cancer | lab-study | — | Source → |
| Study Examines Effectiveness of S-1 and Oxaliplatin in Treating Colorectal Liver Metastases | Colorectal Cancer | phase-2 | The disease-free survival (DFS) at 3 years was 52.9% in the low-dose group. | Source → |
| Researchers Identify Potential Biomarkers for Colorectal Cancer Resistance to Oxaliplatin | Colorectal Cancer | lab-study | — | Source → |
| Rare Liver Damage Linked to Cancer Treatment | Colorectal Cancer | observational | — | Source → |
| Researchers Target Gene to Overcome Oxaliplatin Resistance in Colorectal Cancer | Colorectal Cancer | lab-study | — | Source → |
| Oxaliplatin Transfers into Human Milk, Study Finds | Colorectal Cancer | observational | — | Source → |
| FOLFOX treatment for pancreatic cancer: a study of its effectiveness | Pancreatic Cancer | observational | The median overall survival was 3.9 months, and the median progression-free survival was 1.3 months. | Source → |
| Gene Linked to Chemoresistance in Colorectal Cancer | Colorectal Cancer | lab-study | — | Source → |
| Non-coding RNAs and Colorectal Cancer Resistance to Oxaliplatin | Colorectal Cancer | review | — | Source → |
| Researchers Explore New Way to Deliver Cancer Drug | Colorectal Cancer | review | — | Source → |
| Chemotherapy Sensitizes Colorectal Cancers to Immunotherapy | Colorectal Cancer | lab-study | — | Source → |
| Gene Linked to Colorectal Cancer Treatment Response | Colorectal Cancer | lab-study | — | Source → |
| Oxaliplatin's Effect on Elderly Colon Cancer Patients | Colorectal Cancer | observational | Relapse-free rates were 82.2% vs. 55.6% and 69.6% in AC patients with FU+oxaliplatin vs. AC patients with only FU and non-AC patients, respectively. | Source → |
| Oxaliplatin Resistance in Colorectal Cancer | Colorectal Cancer | lab-study | — | Source → |
| Vorinostat May Improve Effectiveness of Oxaliplatin in Colorectal Cancer Cells | Colorectal Cancer | lab-study | — | Source → |
| New Delivery System for Cancer Treatment Shows Promise | Colorectal Cancer | lab-study | The cytotoxicity of OXA-CuS@UiO-66-NH was greater than that of the OXA alone. | Source → |
| Oxaliplatin sensitivity in colorectal cancer linked to NFS1 enzyme | Colorectal Cancer | lab-study | — | Source → |
| Engineered Milk Vesicles Deliver Cancer Treatment | Colorectal Cancer | lab-study | Drug-loaded Milk EV showed significantly higher incorporation into EGFR expressing cancer cells compared with milk EV without GE11 conjugation. | Source → |
| Combining Capecitabine and Oxaliplatin for Colorectal Cancer Treatment | Colorectal Cancer | observational | The overall response rate was 69.6% with 13 patients attaining a complete response. | Source → |
| New Cancer Treatment Combination Shows Promise in Lung Cancer | Lung Cancer | animal-study | — | Source → |
| Adding Oxaliplatin to Rectal Cancer Treatment Does Not Improve Outcomes | Colorectal Cancer | phase-3 | Three-year disease-free survival was 76.3% for the capecitabine with RT group and 74.1% for the capecitabine and oxaliplatin with RT group. | Source → |
| Colorectal Cancer Treatment Trends in China | Colorectal Cancer | observational | — | Source → |
| Raltitrexed Chemotherapy for Colorectal Cancer: New Study Results | Colorectal Cancer | phase-2 | Median progression-free survival was 10.6 months (95% CI 8.2 - 13.1) and median overall survival was 27.4 months (95% CI 24.1-38.1). | Source → |
| FOLFOX Chemotherapy Shows Promise in Treating Metastatic Pancreatic Tumors | Pancreatic Cancer | observational | Disease control rate (DCR) was 83.3%. | Source → |
| Oxaliplatin Resistance in Colorectal Cancer | Colorectal Cancer | lab-study | — | Source → |
| How Two Cancer Drugs Affect Cells Differently | Lung Cancer | lab-study | — | Source → |
| Improving Cancer Treatment with Targeted Drug Delivery | Colorectal Cancer | animal-study | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.